• Outstanding Seal
  • Antimicrobial properties
  • Promotes per-apical healing
  • Easy obturations and follow-up


BioRoot™ RCS. Succeed.


For more information on this exciting new product go to 
www.septodont.com

 

Article: Volume 45 Number 1 Page 38 - January 2018

Prev    Article P38    Next  Read article

  Dent Update 2018; 45: 38-42

Oral medicine:  Oral Mucosal Ulceration Induced by Alendronic Acid: A Case Series

CPD:  CPD  0:24   (closed)      Self assess

Feedback:  0 comments, 0 ratings

      

Abstract: A number of medications may cause oral ulceration by either systemic or local mechanisms. Alendronic acid tablets, when in prolonged contact with the oral mucosa, are one such medication. When prescribing alendronic acid tablets, it is important to ensure that the patient is able to take them correctly and, if this is not the case, that alternative methods of bone protection are considered. When patients present with oral ulceration, it is important to consider whether a medicine could be causing a localized tissue reaction. This case series highlights three cases of alendronic acid-induced oral ulceration.

Clinical relevance: Practitioners should be aware of the potential oral unwanted effects of medications, including oral ulceration induced by prolonged mucosal contact with alendronic acid.

Author notes: Daniel Finn, BDS(Hons), MFDS RCS(Ed), PGCert, Specialty Dentist in Oral Medicine, Liverpool University Dental Hospital, Anne Field, MDS, DDSc, FDS RCS, Honorary Professor and Consultant in Oral Medicine, Liverpool University Dental Hospital, Bijaya Rajlawat, BChD, MFDS, MBChB, FDS RCS, Consultant in Oral Medicine, Liverpool University Dental Hospital and Christine Randall, BPharm MRPharmS, Senior Medicines Information Pharmacist, North West Medicines Information Centre/Yellow Card Centre North West, Liverpool, UK.

Objective: To be aware of the potential for prolonged contact with alendronic acid to precipitate oral mucosal ulceration and identify those patients particularly at risk from this adverse drug reaction (ADR). Enhanced CPD DO C

BDIA CSIDI